Guillaume Valenzuela

Yesterday’s GE HealthCare session on “Advancing Radiotheranostics: Precision Medicine of Today and the Path Forward” at European Association of Nuclear Medicine (EANM) 2025 in Barcelona brought together an exceptional group of experts and innovators to discuss where the field of #radiotheranostics stands - and where it must go next. 🔹 Key Takeaways: • The necessity of continuous staff education remains a cornerstone for safe, effective, and scalable radiotheranostics practice. • Equally, patient education is essential - to build understanding, confidence, and informed participation throughout the care journey. • Personalized dosimetry is emerging as one of the most critical frontiers - bridging imaging, physics, and therapy to individualize patient care. • While there are great expectations for new radioligands, success will rely on stronger partnerships across the ecosystem - spanning clinical trials, data sharing, and regulatory alignment. Deep thanks to all speakers and panelists (Gustav von Schulthess, Lisa Rowley, Sophie Veldhuijzen van Zanten, Diego Cecchin, and Andrew Nelson), and attendees for the thoughtful discussions, and to the EANM community for continuing to push the boundaries of #PrecisionMedicine. Maxime Teisseire, Jakub Siennicki, #NuclearMedicine

136

4 Comments

📊 Q2 2025 MedTech Market Snapshot: Who’s Leading in Medical Devices? The latest data visualization reveals the Top Selling Medical Devices of MedTech Giants for the first half of 2025 — and the numbers speak volumes. 🔹 Medtronic leads the pack with $33.12B, powered by innovations like the Micra™ leadless pacemaker, MiniMed™ 780G insulin pump, and Intellis™ neurostimulator. 🔹 Johnson & Johnson follows closely at $31.85B, driven by Vistaseal™, Acclarent™, and Biosense Webster™ technologies. 🔹 Stryker holds strong with $22.59B, thanks to the Mako™ surgical robot, Neptune™ waste system, and advanced spine implants. Other standout performers: • Abbott: $18.98B — FreeStyle Libre™, HeartMate 3™, Confirm Rx™ • Boston Scientific: $16.74B — Watchman™, Emblem™, LithoVue™ • BD: $15.40B — Alaris™, Pyxis™, BD MAX™ • GE Healthcare: $13.07B — Revolution CT™, LOGIQ™, Vivid™ • Cardinal Health: $12.49B — Kangaroo™, Curity™, Monoject™ • Intuitive Surgical: $8.35B — da Vinci™ Surgical System • Olympus: $6.96B — EVIS X1™, Thunderbeat™, Visera™ 🧠 This chart isn’t just about revenue — it’s a reflection of clinical impact, technological leadership, and market momentum across surgical robotics, diagnostics, and patient monitoring. #MedTech #MedicalDevices #Q22025 #HealthcareInnovation #MarketLeaders #SurgicalRobotics #InfographicDesign #VisualStorytelling #MedicalTechnology #LinkedInInsights #ABOKHATWAVisuals #DataDrivenDesign #CinematicInfographics

248

10 Comments

Biobeat Technologies Names Raymond W. Cohen as Chairman of the Board of Directors Tel Aviv, Israel & Miami, Florida, Aug. 21, 2025 (Global Newswire) – BioBeat Technologies Ltd, a medical device company that has developed a wearable cuff-less ambulatory blood pressure monitoring system that records and analyzes numerous physiological parameters, today announced the appointment of Raymond W. Cohen as its Chairman of the Board of Directors. Biobeat developed and has received FDA clearance for an easy-to-apply “patch” device that can collect, record and transmit patient data to a cloud-based data center for AI-aided analysis and reporting of physiological parameters, including continuous cuff-less ambulatory blood pressure (ABPM), Sp02, respiration rate, pulse rate, heart rate variability, ECG, temperature and cardiac output. “We welcome Raymond W. Cohen as our new Chairman,” said Arik Ben Ishay, co-founder and CEO of Biobeat. “Ray’s extensive track record in leading, financing and scaling medical technology companies will be invaluable as we look to capitalize on our unique ambulatory technology.” “Biobeat has accomplished what has been an elusive goal for many – a clinically validated and FDA cleared cuff-less ABPM that has the potential to change the use paradigm for measuring ambulatory blood pressure. We see numerous applications for this technology in the new field of renal denervation (RDN) as well as long term monitoring of post-cardiac procedure and CHF patients following discharge from the hospital,” said Mr. Cohen. “I look forward to collaborating with the management team to support the company’s mission to change the way patients are monitored.” Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of life science industry experience. Cohen currently serves on the boards of several innovative healthcare companies, including Kestra (Nasdaq: KMTS); InspireMD (Nasdaq: NSPR); RxSight (Nasdaq: RXST), Nalu Medical as chairman, Archimedes Vascular as chairman, Tulavi Medical as vice chairman, and Spectrum Vascular as an independent director. Mr. Cohen also serves as a venture partner with Paris-based Andera Partners and Beijing-based Sherpa Capital Partners. About BioBeat Technologies, Ltd BioBeat based in Israel and Boca Raton, FL is a privately held company that has developed wearable, non-invasive cuffless ambulatory blood pressure monitoring technology that enables continuous, blood pressure measurements, respiratory rate, Sp02, ECG, pulse rate, body temperature, stroke volume, cardiac output, systemic vascular resistance and other key physiological parameters. By comparison, unlike traditional ABPM system, BioBeat offers a cuff-less small unobtrusive “patch” device with enhanced patient comfort, especially during sleep while collecting and transmitting real time data to a mobile app. Biobeat’s products are 510(k) cleared by the US Food & Drug Administration.

196

21 Comments

We’re thrilled to announce a major milestone in cardiac care: Our Revolution Vibe CT system has received FDA 510(k) clearance—and the first global install is already live at Radiologie du Var – ELSAN in France. This powerful technology delivers full-heart clarity in a single beat, even without ECG trace, and leverages AI to help cut exam time by 50% and double CCTA capacity. It’s designed to meet the growing demand for non-invasive cardiac imaging and support clinicians in delivering faster, more confident diagnoses. The future of cardiac CT is here—and it’s smart, fast, and accessible. #RevolutionVibe #CardiacImaging #FDAclearance #AIinMedicine #GEHealthCare https://lnkd.in/eBF66EDG

227

3 Comments

#MedTech News Week 30, 2025 🛡️ Regulatory Spirair secured 510k for TurbAlign, a bio-absorbable nasal implant that keeps the middle turbinate in place after sinus surgery Elekta added drug-resistant mesial temporal lobe epilepsy to Leksell Gamma Knife indications, giving seizure patients a non-invasive option Philips received clearance for the UroNav Fusion Bx Pro image-guided prostate biopsy platform, fusing fast MRI with live ultrasound Boston Scientific landed expanded labeling for Watchman FLX Pro, letting more high-bleeding-risk AF patients opt for LAA closure 🧪 Clinical XVIVO enrolled the first patient under a continued-access study of its Heart Assist Transport warm-perfusion system while PMA data keep building InterVene, Inc. treated 1st patient with thrombectomy system targeting chronic venous disease complications DeepQure Inc. launched a European feasibility study of its ultrasound renal-denervation system in atrial fibrillation patients BD began a pivotal trial of its ultra-low-volume on-body injector to enable home dosing of fragile biologics AngioDynamics PRESERVE data in European Urology showed NanoKnife IRE can ablate prostate tissue with minimal functional impact 💰 Funding vVARDIS raised $85m to scale drill-free Curodont caries therapy Shoulder Innovations closed a $40m convertible note led by Fidelity to accelerate shoulder arthroplasty rollout Cooler Heads Care iced an oversubscribed $11m Series A for Amma, the only FDA-cleared portable scalp-cooling system Aidoc secured $150m co-led by General Catalyst and Square Peg with NVentures, bringing total funding to $370m for its CARE foundation model Omega Funds locked in $647m for Fund VIII to keep fueling life-science disruptors after a string of exits Abu Dhabi Investment Authority (ADIA) committed $200m to India’s Meril, underscoring the global pull of cost-efficient medtech manufacturing 🤝 Deals & Strategy ZimVie will go private via ArchiMed at $19 per share, a ~99 % premium, valuing the company at ~$730m OrbusNeich Medical Company Ltd. expanded its distribution pact with SonoScape to 12 APAC & EU markets for IVUS systems & VP | MED Group for scoreflexTRIO to the UK GE HealthCare debuted Definium Evo Max digital X-ray with AI-driven workflow Olympus Corporation entered GI endoluminal robotics through a new venture built on Field Robotics assets Surgify Medical Oy partnered with Italy’s Luma to distribute Halo tissue-selective bone-cutting tech nationwide 💡 Tech & Innovation Trinity Biotech unveiled CGM Plus, a modular multi-parameter biosensor poised to challenge incumbent wearables TISSIUM commenced US launch of COAPTIUM Connect, an atraumatic suture-less nerve-repair device following De Novo authorization NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) logged the first commercial implant of its Altius thin-film spinal cord stimulator for chronic pain Heartflow filed for a $100m IPO, betting Wall Street is ready for AI-driven coronary physiology

50

2 Comments